Anders, K.L., Indriani, C., Ahmad, R.A., Tantowijoyo, W., Arguni, E., Andari, B., Jewell, N.P., et al. (2018) The AWED Trial (Applying Wolbachia to Eliminate Dengue) to Assess the Efficacy of Wolbachia-Infected Mosquito Deployments to Reduce Dengue Incidence in Yogyakarta, Indonesia: Study Protocol for a Cluster Randomised Controlled Trial. Trials, 19, Article No. 302.
https://doi.org/10.1186/s13063-018-2670-z

has been cited by the following article:

• TITLE: Leveraging Nanotechnology for Addressing COVID-19: Revealing Antiviral Approaches and Hurdles

  AUTHORS: Mehrnaz Mostafavi, Mahtab Shabani

  KEYWORDS: COVID-19, Coronavirus, Nanomaterials, Nano-Based Vaccine, SARS-CoV-2

  JOURNAL NAME: World Journal of Nano Science and Engineering, Vol.14 No.1, March 6, 2024

  ABSTRACT: The emergence of COVID-19 has caused extensive harm and is recognized as a significant threat to human life worldwide. Currently, the application of nanomedicine techniques in pre-clinical studies related to various infections, such as respiratory viruses, herpes viruses, human papillomavirus, and HIV, has demonstrated success. Nanoparticles, due to their specific attributes, have garnered considerable attention in combating COVID-19. Strategies employing nanomaterials for COVID-19 prevention encompass the development of rapid, precise diagnostic tools, the creation of effective disinfectants, the delivery of mRNA vaccines to the biological system, and the administration of antiretroviral medications within the body. This article focuses on recent research regarding the effectiveness of nano platforms as antiviral measures against coronaviruses. It delves into the molecular characteristics of coronaviruses and the affected target systems, highlighting challenges and limitations in combating SARS-CoV-2. Additionally, it explores potential nanotechnology-based treatments to confront current and future variants of coronaviruses associated with COVID-19 infections.